PLYMOUTH, Mass.--(BUSINESS WIRE)--Oct 28, 2008 - Harvest Technologies Corp. (www.harvesttech.com) announced today that its new patient-education website, www.CLIclinicalstudy.com, is now "live". The site is intended to offer persons who are considering enrolling in the Company's clinical trial and their referring physicians important information related to the study's design, the science that underlies it, and the location of the study's sites.

The Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to Harvest Technologies to conduct a randomized, controlled, double-blind, multicenter clinical trial using the Company's BMAC System to prepare a composition of bone marrow stem cells to treat patients with Critical Limb Ischemia (CLI). This "feasibility trial" will enroll a total of 48 subjects. Subjects who enroll in this study have exhausted all surgical and procedural options and are at extreme risk for major amputation. The BMAC System is a point-of-care device for concentrating a patient's own (autologous) bone marrow stem cells in approximately 15 minutes at the bedside. The clinical study design provides for injecting these cells into the affected limb to reduce the potential for limb amputation. It also will offer data with respect to the safety of this procedure.

Published studies in this area have used complicated methods to process and concentrate adult stem cells from a patient's bone marrow. The BMAC System is the first to offer clinicians a simple, easy point-of-care method to prepare a concentration of stem and precursor cells from a small aspirate of autologous bone marrow in just 15 minutes.

Harvest Technologies is a privately held company based in Plymouth, Mass.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.